Fig. 1 · Structure

Documents & Downloads

Dorzolamide HCL

Cat. No. A10333 CAS 130693-82-2

carbonic anhydrase inhibitor

Dorzolamide HCl is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. Dorzolamide HCl is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Carbonic anhydrase II Ki 1.9 nM
Carbonic anhydrase IV Ki 31 nM
Carbonic anhydrase I Ki 6000 nM

Dorzolamide HCL Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Dorzolamide HCL from 1 published reference. In vitro models include E. faecium HM-952. In vivo models include 8-week-old female C57BL/6 mice.

Dorzolamide HCL In Vitro Studies

Dorzolamide was evaluated against E. faecium HM-952 at 10 × MIC over 24 hours. Bacterial counts remained almost constant but were significantly reduced compared to the DMSO negative control. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Dorzolamide effects on E. faecium bacterial counts

Cell-based study · E. faecium HM-952 [1]

E. faecium HM-952 was treated with Dorzolamide at 10 × MIC for 24 hours. Bacterial counts remained almost constant but were significantly reduced compared to the DMSO negative control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
bacterial countReported result the bacterial count of E. faecium HM-952 remained almost constant over 24 hours but was significantly reduced as compared to the negative control (DMSO).[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 × MIC
Exposure duration
24 hours
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Dorzolamide

The paper names Dorzolamide without stating the salt or form; not verified as the hydrochloride form supplied as A10333. No dose conversion or lot validation.

Results > Dorzolamide exhibits a bacteriostatic effect against VRE (S43); Figure 1 legend (S66)

bacterial count: bacterial count; comparator: negative control (DMSO) — Results > Dorzolamide exhibits a bacteriostatic effect against VRE (S43)

Dorzolamide HCL In Vivo Studies

Dorzolamide was administered to infected female C57BL/6 mice at 10 mg/kg by oral gavage. After 7 days, fecal VRE counts slightly increased compared to day 5, resulting in a 2.69-log10 (99.8%) reduction compared to vehicle-treated mice. [1]

Dorzolamide effects on fecal VRE counts in mice

Animal study · 8-week-old female C57BL/6 mice [1]

Infected female C57BL/6 mice received Dorzolamide at 10 mg/kg by oral gavage. After 7 days, fecal VRE counts slightly increased compared to day 5, resulting in a 2.69-log10 (99.8%) reduction compared to vehicle-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Log10 (CFU/mL) of vancomycin-resistant E. faecium HM-952 in the fecal contents of infected mice.fecal VRE burden 2.69-log10 (99.8%) reduction[1]

Conditions shared by the study groups

Route
oral gavage
Treatment course
quaque die (q.d.) for eight consecutive days
Vehicle
10% DMSO:90% PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dorzolamide 10 mg/kgvehicle (10% DMSO:90% PBS) (negative control)After 7 days of dorzolamide treatment, the count of VRE slightly increased (compared to day 5) resulting in a 2.69-log10 (99.8%) reduction compared to vehicle-treated mice.[1]
Dorzolamide 10 mg/kg
Model: 8-week-old female C57BL/6 mice
Methods and source locations

Compound reported in the paper: Dorzolamide

The paper names Dorzolamide without stating the salt or form; not verified as the hydrochloride form supplied as A10333. No dose conversion or lot validation.

Materials and Methods > In vivo VRE colonization reduction mouse model (S17, S18, S19); Results > Dorzolamide significantly reduced the burden of VRE in the GIT in a colonization reduction murine model (S55); Figure 2 legend (S70)

Log10 (CFU/mL) of vancomycin-resistant E. faecium HM-952 in the fecal contents of infected mice.: Log10 (CFU/mL) of vancomycin-resistant E. faecium HM-952 in the fecal contents of infected mice.; comparator: vehicle (10% DMSO:90% PBS) (negative control) — Results > Dorzolamide significantly reduced the burden of VRE in the GIT in a colonization reduction murine model (S55); Figure 2 legend (S70)

Dorzolamide 10 mg/kg · Materials and Methods > In vivo VRE colonization reduction mouse model (S18, S19); Results > Dorzolamide significantly reduced the burden of VRE in the GIT in a colonization reduction murine model (S55)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 130693-82-2
Applications carbonic anhydrase inhibitor
Formula C10H17ClN2O4S3
Molecular Weight 360.9
Synonyms Trusopt; Cosopt
SMILES
CCN[C@H]1C[C@@H](S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water 12 mg/mL (33.25 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dorzolamide HCL Research References

  1. [1] Abutaleb NS, Elhassanny AEM, Flaherty DP, et al. In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ (2021). PMID: 33850651 DOI: 10.7717/peerj.11059 Source material

Added to your cart

View Cart Checkout
Loading...